Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
featured
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

  • 210 views
  • 23 Nov, 2020
  • 1 location
featured
A Phase 3 Clinical Trial for Patients with Nonalcoholic Steatohepatitis (NASH)

A Phase 3 Clinical Trial for Patients with Nonalcoholic Steatohepatitis (NASH)

  • 588 views
  • 08 Nov, 2020
  • 1 location
Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients

activate FXR. Obeticholic acid (OCA) is a first-in-class selective FXR agonist which has approximately 100 fold greater FXR-agonistic activity in the nanomolar range, as compared to CDCA .It therefore

  • 2 views
  • 13 Jun, 2021
  • 2 locations
Clinical Research of Reducing Medication Regimen for Ursodeoxycholic Acid in Treatment of Stable Primary Biliary Cholangitis

This study explores the feasibility of the reducing medication regimen for Ursodeoxycholic Acid(UDCA) in the treatment of primary biliary cholangitis. The participants will be distributed randomly into two experimental groups and one control group. The two experimental groups will receive reduced dosage of UDCA at different level, while the control …

  • 0 views
  • 27 Jan, 2021
  • 1 location
Combination Antiretroviral Therapy (cART) for PBC

Placebo Controlled, double-blind randomized controlled trial (RCT) with 12 months Tenofovir Disoproxil and Raltegravir for primary biliary cholangitis (PBC) patients unresponsive to Ursodeoxycholic Acid (UDCA). Placebo patients will be offered 12 months open label therapy at unblinding. All patients will be offered an additional 12 months open label therapy. Observational, …

  • 0 views
  • 30 May, 2021
  • 8 locations
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis

cirrhosis requiring liver transplantation or resulting in death. The investigational drug, Obeticholic Acid (OCA) is a modified bile acid and FXR agonist that is derived from the primary human bile acid

cholangitis
obeticholic acid
fibrosis
investigational drug
antimitochondrial antibody
  • 402 views
  • 27 May, 2021
  • 323 locations
Study of OCA in Combination With BZF Evaluating Efficacy Safety and Tolerability in Patients With PBC

Study to determine the effect of the investigational drug obeticholic acid (also known as OCA) in combination with the investigational drug bezafibrate (BZF) in patients with Primary Biliary

bezafibrate
obeticholic acid
cholangitis
  • 0 views
  • 12 May, 2021
  • 38 locations
Identification of Biomarkers Related to Liver Fibrosis as New Therapeutic Targets

is necessary to control the liver fibrosis and thus reduce the risk of carcinoma in this population. The anti-fibrotic drugs are being developed, but so far only alpha-tocopherol and obeticholic acid

  • 0 views
  • 23 Jan, 2021
  • 2 locations
sCD163 in PBC Patients - Assessment of Treatment Response

Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment. sCD163 is a macrophage activation marker shedded into …

cholangitis
macrophage activation
cirrhosis
ursodiol
fibroscan
  • 30 views
  • 07 May, 2021
  • 1 location
Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)

Up to 40% of patients with PBC have an inadequate response to standard treatment with UDCA, hence bezafibrate, a PPAR-agonist is being introduced as add-on therapy in these patients. sCD163, fibrosis markers and bile acid composition are of special interest in PBC. In this study, the investigators will investigate how …

  • 0 views
  • 26 Jan, 2021
  • 2 locations